Long-term safety of hypnotic drugs

Research objective: The objective of this study was to evaluate the long-term safety of hypnotic drugs used in the treatment of insomnia, with particular focus on adverse effects, risk of tolerance and dependence, cognitive consequences, and overall health outcomes associated with prolonged pharmacological therapy. Methodology: This study is based on a narrative review of randomized controlled trials, meta-analyses, and international clinical guidelines concerning the long-term use of hypnotic medications. The analysis included traditional agents such as benzodiazepines and non-benzodiazepine Z-drugs, as well as newer pharmacological options including melatonin receptor agonists and orexin receptor antagonists. Main conclusions: Long-term use of benzodiazepines and Z-drugs is associated with an increased risk of cognitive impairment, falls, traffic accidents, withdrawal symptoms, and the development of psychological and physical dependence. In older adults, prolonged exposure to these agents is additionally linked to a higher risk of dementia and increased all-cause mortality. Newer hypnotic agents demonstrate a more favorable safety profile, with lower dependence potential and minimal tolerance even during extended use. Application of the study: The findings support clinical decision-making by emphasizing the need for time-limited pharmacological treatment of insomnia and the prioritization of non-pharmacological interventions, particularly cognitive-behavioral therapy for insomnia (CBT-I). The study also highlights the importance of regular reassessment of treatment necessity and patient education to minimize long-term risks. Originality/Novelty of the study: This study provides a comprehensive and up-to-date synthesis of evidence on the long-term safety of both traditional and newer hypnotic drugs, directly comparing their risk profiles. By integrating data from clinical trials and guidelines, it contributes to improved understanding of safer long-term management strategies for chronic insomnia.